The National Comprehensive Cancer Network has published updates to its clinical practice guidelines for follicular lymphoma and diffuse large B-cell lymphoma.
The National Comprehensive Cancer Network has issued updates to their clinical practice guidelines, drugs and biologics compendium, radiation therapy compendium, and imaging appropriate use criteria guidelines for pancreatic adenocarcinoma.
Catch up on some of the most recent and practice-changing guideline updates in blood malignancies regarding treatment approaches and prognostic indicators.
The National Comprehensive Cancer Network has issued updates to the primary and second-line therapy options for the treatment of Hodgkin lymphoma.
A panel at the SGO 2018 Annual Meeting on Women’s Cancer convened to achieve consensus on PARP inhibitor use for the treatment and maintenance of ovarian cancer in the context of current standards.
ASCO Issues New Guidelines for Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer
The American Society of Clinical Oncology has released new guidelines to address abiraterone or docetaxel with androgen-deprivation therapy for metastatic prostate cancer that has not been treated with testosterone-lowering agents.
International Workshop on CLL Revises Consensus Guideline Criteria for Prognostic Indicators, Response Assessments
Major advances in the biology and treatment of patients with CLL have prompted the International Workshop on CLL to evaluate and revise the criteria for their consensus guideline in this disease setting.
The National Comprehensive Cancer Network has published updates to their guidelines for acute lymphoblastic leukemia, which include new treatment options for Ph-positive, Ph-negative, and relapsed or refractory disease.
The American Society for Radiation Oncology has issued a clinical guideline for the use of whole-breast radiation therapy that expands the eligibility criteria for hypofractionated therapy.
The American College of Physicians has issued an updated guidance statement recommending an HbA1c level between 7% and 8% in most patients with type 2 diabetes.